Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial-Reference-Cited by-同舟云学术

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Published:2014-11 Issue:12 Volume:15 Page:1311-1318
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Fowler Nathan H,Davis R Eric,Rawal Seema,Nastoupil Loretta,Hagemeister Fredrick B,McLaughlin Peter,Kwak Larry W,Romaguera Jorge E,Fanale Michelle A,Fayad Luis E,Westin Jason R,Shah Jatin,Orlowski Robert Z,Wang Michael,Turturro Francesco,Oki Yasuhiro,Claret Linda C,Feng Lei,Baladandayuthapani Veerabhadran,Muzzafar Tariq,Tsai Kenneth Y,Samaniego Felipe,Neelapu Sattva S

Publisher

Elsevier BV

Subject

Oncology

Reference42 articles.

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma;Blood,1997

2. Follicular lymphoma: 2012 update on diagnosis and management;Freedman;Am J Hematol,2012

3. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia;Badoux;Blood,2011

4. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia;Chen;J Clin Oncol,2011

Cited by 233 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysregulated gene expression of SUMO machinery components induces the resistance to anti-PD-1 immunotherapy in lung cancer by upregulating the death of peripheral blood lymphocytes;Frontiers in Immunology;2024-08-15

2. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial;eClinicalMedicine;2024-08

3. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203;Hematological Oncology;2024-04-10

4. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

5. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1;Scientific Reports;2024-01-31